-
Posted by
Two Blokes Jul 3 -
Filed in
Stock
-
7 views
AUSTIN, Texas--(BUSINESS WIRE)---- $IPA #AI--ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) (“IPA” or the “Company”), an AI-powered biotherapeutics company, today announced a new validation study supporting the generalizability of its proprietary epitope mapping platform, LENSai, powered by IPA's patented HYFT\u00ae technology. The newly released benchmark shows that the platform consistently delivers high predictive performance, even on complexes not used during training. “It's generally assumed that AI can only m.
